Why Epic’s Judy Faulkner Rejects the MBA Mindset

At Forbes Healthcare Summit, Epic CEO Judy Faulkner explained why the company’s long-protected independence and unconventional management approach have been central to its dominance as an EHR vendor. Now, she says the company’s future will depends on how it uses its massive data stores to support AI-powered clinical decisions. The post Why Epic’s Judy Faulkner…

Read More

Relapses Don’t ‘Happen in Clinics’: Empathy Health Technologies Secures $7.6M for Sobriety App

Empathy Health’s $7.6 million round was led by HealthX Ventures and included participation from Nina Capital, Ikigai Healthcare Funds, American Heart Association Ventures, Suncoast Ventures, Cortado Ventures and Wilson Sonsini Investment Company. The post Relapses Don’t ‘Happen in Clinics’: Empathy Health Technologies Secures $7.6M for Sobriety App appeared first on MedCity News.

Read More

Debunked Episode 22: With ACA Subsidies Set to Expire and the Open Enrollment Window Closing, Members of Congress Brainstorm Alternatives

What are the alternatives to extending ACA subsidies for the 22 million people who purchase health plans on the ACA Marketplace? That’s the focus of the latest episode of the Debunked podcast, hosted by MedCity News Editor in Chief Arundhati Parmar and Samir Batra, managing partner of Health Innovation Pitch. The post Debunked Episode 22:…

Read More

Modern Interoperability: How APIs Can Heal a Fragmented System

The go-to mechanisms for differential payment – network design, case management, quality measurement and prior authorization – increasingly rely on APIs capable of handling not only claims data but, more importantly, the clinical data critical to intelligent decision-making. The post Modern Interoperability: How APIs Can Heal a Fragmented System appeared first on MedCity News.

Read More

What Is Philips Showing Off at RSNA This Year?

Philips showcased two major imaging innovations at RSNA 2025 — one a CT system that integrates AI into its hardware, and the other a new helium-free MRI model that embeds AI directly into signal acquisition. Both aim to improve image quality, efficiency and ease of integration — but commercial availability and real-world adoption are still…

Read More

Pharvaris Drug for Rare Swelling Disease Meets Phase 3 Goals; FDA Filing Planned for 2026

Pharvaris’s deucrictibant met the main and secondary goals of its Phase 3 test as an on-demand treatment for swelling attacks caused by the rare disease hereditary angioedema. Pharvaris’s capsule could compete against Kalvista Pharmaceuticals’ Ekterly, an HAE pill approved by the FDA over the summer. The post Pharvaris Drug for Rare Swelling Disease Meets Phase…

Read More